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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
probiotics reduce the incidence of upper respiratory tract infections (URTIs) in adult athletes.
STUDY DESIGN: A systematic review of three placebo-controlled randomized trials. The
articles were published in peer reviewed journals between 2008 and 2018 in the English
language.
DATA SOURCES: Three placebo-controlled, single- or double-blinded, randomized trials
comparing the efficacy of placebo vs. probiotics in reducing URTI episodes in athletes over the
age of 18 years old. The articles were found using PubMed and Cochrane via key words.
OUTCOME MEASURED: The outcome measured compared placebo to probiotics by the
number of URTI episodes determined by patient-reported daily symptom logs confirmed by a
physician when possible.
RESULTS: One study showed a significant difference in probiotics reducing the incidence of
URTIs (Strasser B, Geiger D, Schauer M, et al. Nutrients. 2016;8(11):10.3390/nu8110752. doi:
E752) while the studies by Haywood et al (J Sci Med Sport. 2014;17(4):356-360. doi:
10.1016/j.jsams.2013.08.004) and Cox et al (Br J Sports Med. 2010;44(4):222-226. doi:
10.1136/bjsm.2007.044628) were determined to have an insignificant difference.
CONCLUSION: The answer to whether probiotics reduce the incidence of URTIs in adult
athletes is inconclusive in the analysis of the selected three studies.
KEY WORDS: probiotics, human intestinal microbiota, athlete, respiratory, infection
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INTRODUCTION
Upper respiratory tract infections (URTIs), are located in the upper respiratory tract
including the mouth, nose, throat, larynx, and trachea.1 It is a group of infections that can be
more specifically diagnosed as nasopharyngitis (also known as the common cold), sinusitis,
pharyngitis, laryngitis, and laryngotracheitis. There are a wide range of signs and symptoms for
the common cold that include: nasal congestion, sneezing, sore throat, itchy or watery eyes,
cough, hoarseness, headache, fatigue or malaise, and fever. Nasal congestion is the most
common presentation occurring in 80% of patients; sneezing and sore throat are the next most
common symptoms of the common cold. Additional symptoms are specific to other URTIs, such
as sinusitis, including purulent discharge and facial congestion.
URTIs are most common in the winter months due to increased time spent indoors.1 The
low humidity in the winter also allows the typical viruses of URTIs to thrive. Diagnosis is made
on clinical findings and cultures are rarely needed. The direct cost of treating this illness in the
US is $17 billion per year.2
While common in the general population, URTIs are the most common type of infection
in athletes.3 High intensity trained athletes are at a higher risk of URTIs accounting for more
than half the number of acute illnesses in adult athletes.4,5 The high incidence is partially due to
the intensity of exercise, which reduces immune function, but also as a consequence of exposure
to teammates and traveling in close proximity.3 Moderate levels of exercise have shown to
decrease the incidence of illness. However, athletes partake in intense and prolonged training
which depresses immunity.6 URTIs are also costly to the athlete in terms of lost training time
and, for professional athletes, loss in income when missing competitions.7
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The same medications used to treat URTIs in the general population can be used with
athletes but with caution and provider discretion.3 For example, antibiotics can have unfavorable
implications for athletes such as antibiotic-associated diarrhea and fatigue. Other agents have
specific adverse effects that would be wise to avoid for an athlete. Fluoroquinolones have an
increased risk of tendon rupture, tetracyclines can cause photosensitivity, and macrolides and
fluoroquinolones can induce QT prolongation seen on an ECG. Medications used for
symptomatic relief can also be problematic. Oral decongestants can contain banned substances
for athletes competing and cause arrhythmias, antihistamines can cause sedation, and antipyretics
can mask a fever.1,3
URTIs are unfavorable for an athlete’s performance due to their symptomatic effects and
treatment side effects. Prevention of the illness is ideal and is key for reducing the incidence of
URTIs.1 Hand hygiene is the most preventative action against URTIs. Others include not sharing
personal items (towels, water bottles, etc.), isolation of sick team members, proper nutrition,
adequate sleep, and appropriate training schedules.8 However, following these recommendations
may not always be possible in competitive athletes. The use of probiotics have been shown to
have health benefits such as increased immunity and could prevent a person from acquiring a
URTI to begin with.9,10 This paper evaluates three randomized, placebo-controlled trials
determining whether the use of probiotics compared to placebo decreases the incidence of URTIs
in adult athletes.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not probiotics
reduce the incidence of upper respiratory tract infections (URTIs) in adult athletes.
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METHODS
The selection of studies for this systematic review included three placebo-controlled
randomized trials that were either single- or double-blinded. The population was made up of
healthy athletes that were adults, defined as 18 years of age and older. The problem addressed
the use of oral probiotics to reduce the incidence of URTIs. The intervention in the first two
studies6,7 used a multi-species probiotic while the intervention of the third study11 utilized a
single-species probiotic. These studies compared the treatment group receiving a probiotic to the
experimental group receiving a placebo. The demographics and characteristics of the three
studies are summarized in Table 1.
The author of this review searched the PubMed and Cochrane databases using various
combinations of the following key words: probiotics, human intestinal microbiota, athlete,
respiratory, and infection. Articles were selected based on relevance to the question of this study
and resulting in patient oriented evidence that matters (POEM). Inclusion criteria consisted of
single- or double-blinded randomized control trials (RCTs) or other primary research studies
published in peer-reviewed journals within the previous 10 years (2008-2018). Exclusion criteria
included studies that did not measure symptoms and probiotic intervention administered through
consumption of fermented foods. All articles were published in English and the summary of
statistics for each study used p-values.
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Table 1. Demographics & characteristics of included studies
Study

Type

Strasser6
(2016)

Doubleblind,
placebo,
RCT

33

Haywood7 Single(2014)
blind,
placebo,
RCT
Cox11
(2010)

Doubleblind,
placebo,
RCT

#
W/
pts D

Age
(yrs)

Inclusion
Criteria

Exclusion
Criteria

Interventions

4 20-35 Athletes with a
cardiorespiratory response
and fitness
≥150% of
reference
values during
maximal
exercise

Smokers,
history of
muscle
disorders;
heart, kidney,
lung,
neurologic or
psychiatric
disease

Multi-species probiotic:
1.0 x
Bifidobacterium bifidum 10^10
Bifidobacterium lactis
Enterococcus faecium
Lactobacillus acidophilus
Lactobacillus brevis
Lactococcus lactis
VS. placebo

34

4 24+/– Competing,
3.6* male, elite
rugby union
players

N/A

Multi-species probiotic:
Lactobacillus gasseri
Bifidobacterium bifidum
Bifidobacterium longum
VS. placebo

3.0 x
10^9

20

0 27.3
+/–
6.4*

N/A

Single-species probiotic:
L fermentum
VS. placebo

1.2 x
10^10

Healthy elite
male distance
runners

Dose✝

W/D: withdrawal
* mean +/– standard deviation
✝ Total Dose (CFUs / day)

OUTCOME MEASURED
The outcome and how it was measured was that of patient oriented evidence that matters
(POEM) since it was a decrease in URTI symptoms in the patient. The outcome was determined
to be episodes, or incidence, of URTIs. This was clearly defined in two studies as one or more
symptoms for two or more consecutive days.6,7 The third study by Cox did not define what was
considered an “episode” of a URTI. 11 It only stated that symptoms were recorded by participants
and reviewed by a sports doctor for “coding of reported episodes of illness.”11 The outcome was
measured by patient-reported daily symptom logs confirmed by a physician when possible. The
studies vary in what symptoms were recorded for a URTI due to the wide range of symptoms
acknowledged in the introduction. All three studies included sore throat and runny nose among
their listed URTI symptoms. The additional symptoms are listed in Table 2.

Zora, Probiotics Reducing URTIs 5

Table 2. Symptoms used for URTI diagnosis in each study
Study

Symptoms of URTIs

Strasser6 (2016)

Sore throat
Runny nose
Cough
Fever
Weakness

Haywood7 (2014)

Sore throat
Runny nose
Stuffy nose
Sneezing

Cox11 (2010)

Sore throat
Runny nose
Cough
Sneezing
Chest Congestion

RESULTS
Three randomized control trials were evaluated in this systematic review to evaluate
whether daily oral probiotic intake reduced the incidence of URTIs in adult athletes. All three
studies compared oral probiotics to placebo for the decrease in incidence of URTIs and assessed
the significance of results by use of a p-value.
The study by Strasser was specific in its inclusion criteria. It included participants of both
genders within an age range of 20 to 35 years old, who were nonsmokers, had no history of
muscle disorders, and did not have heart, kidney, lung, neurologic and psychiatric disease. 6 The
participants also had to have a “cardiorespiratory response and fitness of ≥150% of reference
values during maximal exercise.”6 This study did not state the type of sport participated by the
athletes, only that they were “trained volunteer athletes.”6 It was conducted in the winter months
(January to March).6
Participants were asked to refrain from the use of anti-inflammatory drugs, antibiotics,
alcohol, additional probiotics and fermented dairy products such as yogurt or any yogurt-based
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products. Supplements, fish oil, vitamins, and minerals were also restricted to prevent
interference with results. Use of any of the restrictions would cause withdrawal from the study.6
Strasser used a double-blinded model meaning the treatment group was unknown to both
the researchers and participants. 6 A third party was utilized to randomize the participants to
either the probiotic or placebo group for three months. The probiotic used contained six strains
chosen for their “survival in the gastrointestinal tract, activity, intestinal barrier function, and
anti-inflammatory properties.”6 See Table 1 for specific strains.
The probiotic was in the form of a sachet that needed to be combined with water. The
participants randomized to the probiotic were instructed to take the combination once a day
before breakfast, receiving 1×1010 colony forming units per day (CFUs/day). 6 The participants
randomized to the placebo group received the same instructions and sachets identical in
appearance. Participants of both groups were asked to complete a questionnaire created by
Strasser about the URTI symptoms experienced listed in Table 2. 6
There was a >95% compliance rate to both treatments based on all returned sachets.6 The
author also reported a “high level of no replies” to its questionnaire but did not indicate a
percentage or whether there was a statistically significant difference.6
Multiple outcomes were measured in the study but this review only analyzed the
incidence of URTIs shown in Table 3. The study used the Wilcoxon-signed rank and Friedman
test (although it was not explicitly clear) to calculate the p-value.6 Out of 16 reported URTI
episodes, 11 were in participants taking the placebo and only 5 in those taking a probiotic. This
resulted in a p-value of 0.016.6 With a cutoff of <0.05, Strasser showed a statistically significant
difference between the two treatments with more occurring with the placebo treatment.6
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Table 3. Incidence of URTIs in probiotic and placebo treatment groups, Strasser6 (2016)
Total URTI
episodes

Episodes of URTI with
probiotic

16

Episodes of URTI with
placebo
5

p-value
11

0.016

The study by Haywood had a population of elite, male rugby players competing in the
area’s premier union competition but did not include additional inclusion or exclusion criteria. 7
It also did not explicitly state that the participants were adults but was assumed based on the
mean age and standard deviation provided (see Table 1). The study was conducted in the winter
months of New Zealand (May to July).7
During the study, participants were asked to refrain from consumption of probiotic and
prebiotic enriched food, including yogurt, and any supplements such as additional probiotics,
vitamins, and minerals.7 The study did not require abstinence from medications but did ask them
to report any that were used.7
Haywood used a crossover trial study design meaning participants were randomized to
the probiotic or placebo for four weeks, had a washout period of four weeks, and then switched
to the opposite group for an additional four weeks.7 The researchers of the study randomized the
participants making it single-blinded as only the participants did not know which treatment they
were receiving.
The probiotic used contained three strains (see Table 1). The strains were chosen due to
their acid-resistance, previous studies showing benefits for athletes, and a lack of need to be
refrigerated.7 Participants of both groups were instructed to consume one capsule by mouth
everyday at the same time and complete the questionnaire about his symptoms. When taking the
probiotic, the participant received 3.0 x 109 CFUs/day.7
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Adherence to the treatment was good with no significant statistical difference between
the probiotic and placebo trials.7 The study also reported that participant blinding also appeared
to be effective.7
The Haywood study showed a higher incidence of URTIs with the placebo group versus
the participants taking probiotics as shown in Table 4. 7 Nineteen episodes were recorded in
participants using the placebo compared to 16 episodes in participants taking the probiotics.
“Wilcoxon’s matched-pairs signed ranks test” was used to determine a p-value of 0.366.7 There
was no statistically significant difference since it is above the cutoff of 0.05.
Table 4. Incidence of URTIs in probiotic and placebo treatment groups, Haywood7 (2014)
Total URTI
episodes

Episodes of URTI with
probiotic

35

Episodes of URTI with
placebo
16

p-value
19

0.366

The study by Cox included male athletes described as competitive “highly-trained
distance runners.” 11 This study did not report further inclusion and exclusion criteria nor
explicitly state that the participants were adults. An assumption was made based on the mean age
and standard deviation provided (see Table 1).11 It was conducted over the course of four winter
months.11
The Cox study asked its participants to refrain from yogurt and yogurt-based products for
the entirety of the study. 11 Supplements and drugs (over-the-counter and prescribed) were not
restricted but recorded.
This study was also a crossover trial design, meaning participants took the probiotic or
placebo for four weeks (28 days), had a washout period of four weeks, and then switched to the
opposite group for an additional four weeks.11
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An independent third party randomized the participants to either begin with the probiotic
or placebo group making it double-blinded. 11 The researchers were also not aware of the
allocations until after the completion of the study. The participants were instructed to take three
capsules twice a day with food. The probiotic capsule contained one strain with a total daily dose
of 1.2 x 1010 CFUs/day. See Table 1 for strain. The placebo capsule was identical in appearance.
The participants of both groups were instructed to keep a daily symptom log. The URTI
symptoms used in the questionnaire are listed in Table 2.
The capsule intake compliance for the study was self-reported on a scale of 1-5 with 1
meaning no compliance and 5 representing total compliance. Compliance for the probiotic and
placebo treatments were similar; 3.9 and 4.2 respectively.11
The Cox study evaluated multiple outcomes, however, this review only looked at the
incidence of URTIs. 11 The results showed a total of 13 URTI episodes: 9 in participants taking
the placebo and 4 with the probiotic. Using the χ2 analysis, the p-value was 0.24 which does not
show a statistically significant difference.11 See Table 5 for the Cox study results. 11
Table 5. Incidence of URTIs in probiotic and placebo treatment groups, Cox11 (2010)
Total URTI
episodes

Episodes of URTI with
probiotic

13

Episodes of URTI with
placebo
4

p-value
9

0.24

Safety and Tolerability
None of the three studies reported any adverse events or issues with tolerability.6,7,11
DISCUSSION
The results from the studies suggest that probiotics could be used to prevent URTIs in
adult athletes. All studies showed less episodes of URTIs in the probiotic group compared to the
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placebo, however, only one was determined to be statistically significant. There are several
considerations for these results.
The Strasser study was unclear on the sport the athletes participated in and possibly
included more than one sport. 6 It was also the only study that did not use a crossover design
making it difficult to conclude effectiveness for all adult athletes. The Haywood study was
limited by only being single-blinded possibly resulting in bias since defining a URTI involves a
subjective component. 7 The Cox study required a greater number of capsules to be taken more
frequently likely decreasing compliance. 11 Overall, the results are unable to be generalized due
to only one study including female participants.6 The three studies also assessed athletes of
different sports.6,7,11
Probiotics with a variety of strains and doses are readily available in pharmacies and
supermarkets across the US as well as available online. Since they are over-the-counter drugs, a
prescription is not necessary. However, insurance may cover them if a medical professional
prescribes it for a specific medical condition.12 It is unclear whether a URTI would be an
approved condition, though this would likely vary between insurance companies. It is also
difficult to determine if the use of probiotics is cost-effective because preventing the illness may
be worth the price to the athlete.
Probiotics, like any other form of treatment, should be used with caution. Adverse effects
of probiotics include intestinal bloating and flatulence.13 There are no known drug interactions
and toxicology information is limited. Probiotics have been studied to determine the effects on
several conditions including depression, diabetes, eczema, dyslipidemia, infections, and diarrhea.
There is no clear evidence for specific strains used in established clinical conditions.
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CONCLUSION
The answer to whether probiotics reduce the incidence of URTIs in adult athletes is not
conclusive in the analysis of the selected three studies. Only one study6 revealed a statistically
significant difference in probiotics reducing the incidence while the other two studies7,11 had an
insignificant difference. Analyzed together, these results only show that the evidence is
inconclusive.
A major flaw in these studies is the variety of symptoms used to diagnose a URTI. Each
study had a list of symptoms used to indicate a URTI with only two symptoms being the same
for all studies. A standardized questionnaire and follow up with a medical provider would
provide a more accurate infection diagnosis. This should be considered for future research.
Subsequent studies should also consider the crossover model of both probiotics and
placebo with a wash-out period in participants. This would be beneficial as individual
participants may respond differently to probiotics. Various strains of probiotics should also be
studied. Perhaps the one study with significant difference was due to the strains of probiotics
used.6 The same could be said for the type of sport that was being studied; perhaps its
effectiveness depends on the type of sport and training one participates in. Finally, it should also
be studied whether there’s a difference between genders.
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